Biotech, Medical Device & Pharma Startup News

Get news straight to your inbox by signing up for our free eNewsletters

  • Aer Therapeutics Raises $36M for Novel Approach to COPD

    Aer’s inhaled formulation targets the mucus plugs obstructing COPD patients’ airways.

  • Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1

    Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1.

  • Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced today the appointment of Thomas Ichim, Ph.D., as President, and Chief Executive Officer of Campbell Neurosciences.

  • Enveric Biosciences today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.

  • Seamless Launches with $12.5M for Programmable Recombinases Platform

    Seamless Therapeutics launched Wednesday with $12.5 million in seed financing to develop its programmable recombinases for gene editing.

  • Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift

    Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.

  • Amplifier Launches to Bring First AMPK Activator to the Clinic

    Cambrian BioPharma announced the launch of Amplifier Therapeutics, a biotech focused on developing a clinical-stage AMPK activator.

  • Closing the Opportunity Gap: How Inceptor Bio Supports Women Leaders

    Women are often at the forefront of innovation, making up nearly half of the life sciences industry despite a shrinking but persistent wage gap. Inceptor Bio is at the forefront of closing inequality.

  • Starlight Therapeutics Inc., a Lantern subsidiary, will focus exclusively on the clinical development of therapies for CNS (central nervous system) and brain cancers with limited or no effective therapeutic options.

  • Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.

  • George Church-Backed Thymmune Launches to Target Overlooked Organ

    Thymmune is backed by an A-list team of investors including Pillar VC, former Alnylam CEO John Maraganore and famed geneticist George Church.

  • Zymtronix, Inc., a groundbreaking new biotechnology company, today announced that Dr. Thomas Videbaek, biotech industry veteran and former Executive Vice President (EVP) of Novozymes, is joining its Board of Directors.

  • Alnylam Vets Raise $193M to Solve Gene Therapy's Biggest Hurdle - Delivery

    Aera Therapeutics emerged from stealth mode Thursday with a platform based on the work of Feng Zhang, Ph.D. and ex-Alnylam executive Akin Akinc at the helm.

  • Alexis Borisy and Co. Raise $520M for New Model VC

    Curie.Bio launched this week with $520 million to take early startups from ground zero through Series A funding.

  • AstraZeneca Spin-off Aristea Folds After Safety Issues End Lead Program

    Due to safety concerns, Aristea Therapeutics announced Friday that it was discontinuing the development of its Phase II lead program. As a result, the San Diego-based biotech is also dissolving its business.

  • FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, announced they are the fastest rising biotech offering in StartEngine’s history surpassing $1 million of new investments on the first day of its Reg CF offering.

  • Swedish medtech startup Syntach AB has been awarded up to €15 million in equity financing by European Innovation Council (EIC) for the development of the Syntach Cardiac Support System, a breakthrough device for patients with heart failure.

  • Selux Diagnostics announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Next Generation Phenotyping (NGP) System.

  • Oncotelic Therapeutics, Inc announced the launch of Pet2DAO Inc., a wholly owned subsidiary of Oncotelic, and its associated token PDAO.

  • TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company.

  • Source:

    Donovan Larsen

    Donovan is a columnist and associate editor at the Dark News. He has written on everything from the politics to diversity issues in the workplace.

    Related Articles

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Back to top button